Literature DB >> 24529565

Low bone mineral density is associated to poor glycemic control and increased OPG expression in children and adolescents with type 1 diabetes.

Melina B Loureiro1, Marcela A G Ururahy2, Francisco P Freire-Neto2, Gustavo H M Oliveira2, Valéria M G Duarte2, André D Luchessi2, José Brandão-Neto3, Rosario D C Hirata4, Mario H Hirata4, José J Maciel-Neto5, Ricardo F Arrais6, Maria G Almeida2, Adriana A Rezende2.   

Abstract

AIMS: To investigate early alterations on bone mineral density (BMD) and RANK, RANKL and OPG mRNA expression in peripheral blood leukocytes (PBL) in children and adolescents with type 1 diabetes (T1D) and the relationship with glycemic control and bone biomarkers.
METHODS: This cross-sectional study included 75 children and adolescents with T1D and 100 individuals without diabetes (normoglycemic-NG) aged 6-20 years old. T1D individuals were considered to have good (T1DG) or poor (T1DP) glycemic control according to the values of HbA1c. Phosphorus, magnesium, total and ionized calcium, osteocalcin, alkaline phosphatase and tartaric-resistant acid phosphatase (TRAP) values were determined in blood samples. BMD was measured by DEXA. RANK, RANKL and OPG mRNA expression was measured in PBL by real-time PCR.
RESULTS: Osteocalcin values were decreased in diabetic groups in comparison to NG group (p<0.05), and a negative correlation with both serum glucose (r=-0.265, p<0.01) and Hb1Ac (r=-0.252, p<0.01) in T1D group was found. BMD was lower in diabetic groups in comparison with NG group (p<0.05) and a negative correlation was observed between BMD and both serum glucose (r=-0.357, p<0.01) and HbA1c (r=-0.351, p<0.01) in T1D group. OPG mRNA expression was significantly increased in T1D and T1DP groups in comparison with NG group (p<0.05). In conclusion, children and adolescents with early onset T1D presented low bone mineral density associated to unsatisfactory glycemic control, increased OPG mRNA expression and low osteocalcin concentration.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Bone metabolism; Diabetic osteopathy; OPG expression; Type 1 diabetes

Mesh:

Substances:

Year:  2014        PMID: 24529565     DOI: 10.1016/j.diabres.2013.12.018

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  17 in total

1.  Local bone interaction between renin-angiotensin system and kallikrein-kinin system in diabetic rat.

Authors:  Yong Li; Guang-Si Shen; Chen Yu; Guang-Fei Li; Jun-Kang Shen; You-Jia Xu; Jian-Ping Gong
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 2.  Effects of Type 1 Diabetes on Osteoblasts, Osteocytes, and Osteoclasts.

Authors:  Evangelia Kalaitzoglou; Iuliana Popescu; R Clay Bunn; John L Fowlkes; Kathryn M Thrailkill
Journal:  Curr Osteoporos Rep       Date:  2016-12       Impact factor: 5.096

Review 3.  Skeletal growth and bone mineral acquisition in type 1 diabetic children; abnormalities of the GH/IGF-1 axis.

Authors:  Manish Raisingani; Brar Preneet; Brenda Kohn; Shoshana Yakar
Journal:  Growth Horm IGF Res       Date:  2017-04-28       Impact factor: 2.372

Review 4.  Type 1 diabetes and risk of fracture: meta-analysis and review of the literature.

Authors:  V N Shah; C S Shah; J K Snell-Bergeon
Journal:  Diabet Med       Date:  2015-06-12       Impact factor: 4.359

5.  Ursolic acid derivative ameliorates streptozotocin-induced diabestic bone deleterious effects in mice.

Authors:  Su-Guo Yu; Cheng-Jie Zhang; Xiu-E Xu; Ji-Hua Sun; Li Zhang; Peng-Fei Yu
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

6.  Estrogen Deficiency Exacerbates Type 1 Diabetes-Induced Bone TNF-α Expression and Osteoporosis in Female Mice.

Authors:  Sandi Raehtz; Hayley Bierhalter; Daniel Schoenherr; Narayanan Parameswaran; Laura R McCabe
Journal:  Endocrinology       Date:  2017-07-01       Impact factor: 4.736

7.  Biochemical Markers of Bone Turnover in Older Adults With Type 1 Diabetes.

Authors:  Mishaela R Rubin; Ian H de Boer; Jye-Yu C Backlund; Valerie Arends; Rose Gubitosi-Klug; Amisha Wallia; Naina Sinha Gregory; Annette Barnie; Andrew J Burghardt; John M Lachin; Barbara H Braffett; Ann V Schwartz
Journal:  J Clin Endocrinol Metab       Date:  2022-05-17       Impact factor: 6.134

8.  Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.

Authors:  C Tsentidis; D Gourgiotis; L Kossiva; A Doulgeraki; A Marmarinos; A Galli-Tsinopoulou; K Karavanaki
Journal:  Osteoporos Int       Date:  2015-11-20       Impact factor: 4.507

9.  Protection against T1DM-Induced Bone Loss by Zinc Supplementation: Biomechanical, Histomorphometric, and Molecular Analyses in STZ-Induced Diabetic Rats.

Authors:  Raul Hernandes Bortolin; Bento João da Graça Azevedo Abreu; Marcela Abbott Galvão Ururahy; Karla Simone Costa de Souza; João Felipe Bezerra; Melina Bezerra Loureiro; Flávio Santos da Silva; Dáfiny Emanuele da Silva Marques; Angélica Amanda de Sousa Batista; Gisele Oliveira; André Ducati Luchessi; Valéria Morgiana Gualberto Duarte Moreira Lima; Carlos Eduardo Saraiva Miranda; Marcus Vinicius Lia Fook; Maria das Graças Almeida; Luciana Augusto de Rezende; Adriana Augusto de Rezende
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

Review 10.  Mechanisms of altered bone remodeling in children with type 1 diabetes.

Authors:  Giacomina Brunetti; Gabriele D'Amato; Stefania De Santis; Maria Grano; Maria Felicia Faienza
Journal:  World J Diabetes       Date:  2021-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.